Erythromycin, cutaneous

Generic name
Erythromycin, cutaneous
Brand name
ATC Code
D10AF02
Compare …

Erythromycin, cutaneous

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No studies have been carried out into the pharmacokinetic parameters of cutaneous erythromycin in children.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Acne vulgaris
  • Cutaneous
    • 10 years up to 18 years

      • 2% formulation of erythromycine: apply to the affected areas twice daily (in the morning and in the evening). In the event of side effects, lower the frequency to once daily

      • According to the NHG (Dutch College of General Practitioners) standard for acne of 2017: In combination with benzoyl peroxide, adapalene or tretinoin: 1% erythromycin once daily in the morning combined with once daily benzoyl peroxide/adapalene or tretinoin in the evening, minimum 6 weeks and maximum 6 months.

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Itching, erythema, burning sensation, dryness, flaking,

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ANTI-ACNE PREPARATIONS FOR TOPICAL USE

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Retinoids for topical use in acne
D10AD03
D10AD53
D10AD01
Peroxides
D10AE01
Antiinfectives for treatment of acne
D10AF51
D10AF01
D10AF51
Other anti-acne preparations for topical use
D10AX03

References

  1. Lesher JL Jr,et al, An evaluation of a 2% erythromycin ointment in the topical therapy of acne vulgaris, J Am Acad Dermatol., 1985, Mar;12(3), 526-31
  2. Shahlita AR, Topical erythromycin v clindamycin therapy for acne. A multicenter, double-blind comparison, Arch Dermatol, 1984, Mar;120(3), 351-5
  3. Rapaport M, et al, Evaluation of topical erythromycin and oral tetracycline in acne vulgaris, Cutis. :,, 1982, Jul;30(1), 122-6, 130, 132-5
  4. Pochi PE, et al, Erythromycin 2 percent gel in the treatment of acne vulgaris, Cutis, 1988 Feb, 41(2), 132-6
  5. Glass D, et al, A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris, Dermatology, 1999, 199(3), 242-7
  6. Bruinsma M, et al, NHG Standaard Acne (derde herziening), Huisarts Wet, 2017 (april)

Changes

Therapeutic Drug Monitoring


Overdose